Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study
- PMID: 28666722
- PMCID: PMC7771352
- DOI: 10.1016/j.urolonc.2017.06.001
Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study
Abstract
Purpose: Few studies have examined the role of radiation therapy in advanced penile squamous cell carcinoma. We sought to evaluate the association of adjuvant pelvic radiation with survival and recurrence for patients with penile cancer and positive pelvic lymph nodes (PLNs) after lymph node dissection.
Materials and methods: Data were collected retrospectively across 4 international centers of patients with penile squamous cell carcinoma undergoing lymph node dissections from 1980 to 2013. Further, 92 patients with available adjuvant pelvic radiation status and positive PLNs were analyzed. Disease-specific survival (DSS) and recurrence were analyzed using the Kaplan-Meier method and multivariable Cox proportional hazards model.
Results: 43% (n = 40) of patients received adjuvant pelvic radiation after a positive PLN dissection. Median follow-up was 9.3 months (interquartile range: 5.2-19.8). Patients receiving adjuvant pelvic radiation had a median DSS of 14.4 months vs. 8 months in the nonradiation group, respectively (P = 0.023). Patients without adjuvant pelvic radiation were associated with worse overall survival (hazard ratio [HR] = 1.7; 95% CI: 1.01-2.92; P = 0.04) and DSS (HR = 1.9; 95% CI: 1.09-3.36; P = 0.02) on multivariable analysis. Median time to recurrence was 7.7 months vs. 5.3 months in the radiation and nonradiation arm, respectively (P = 0.042). Patients without adjuvant pelvic radiation was also independently associated with higher overall recurrence on multivariable analysis (HR = 1.8; 95% CI: 1.06-3.12; P = 0.03).
Conclusions: Adjuvant pelvic radiation is associated with improved survival and decreased recurrence in this population of patients with penile cancer with positive PLNs.
Keywords: Adjuvant radiation; Lymph node dissection; Penile cancer; Recurrence; Survival.
Copyright © 2017 Elsevier Inc. All rights reserved.
Figures



Comment in
-
Re: Adjuvant Pelvic Radiation is Associated with Improved Survival and Decreased Disease Recurrence in Pelvic Node-Positive Penile Cancer after Lymph Node Dissection:J Urol. 2019 Feb;201(2):226-227. doi: 10.1097/01.JU.0000553021.51617.69. J Urol. 2019. PMID: 30634337 No abstract available.
Similar articles
-
Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study.Urol Oncol. 2015 Nov;33(11):496.e17-23. doi: 10.1016/j.urolonc.2015.05.008. Epub 2015 Jun 10. Urol Oncol. 2015. PMID: 26072110
-
Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma.BJU Int. 2017 Apr;119(4):591-597. doi: 10.1111/bju.13686. Epub 2016 Nov 8. BJU Int. 2017. PMID: 27753187
-
Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration.J Urol. 2015 Sep;194(3):696-701. doi: 10.1016/j.juro.2015.03.090. Epub 2015 Mar 20. J Urol. 2015. PMID: 25801766
-
Lymphadenectomy in the surgical management of penile cancer.Eur Urol. 2009 May;55(5):1075-88. doi: 10.1016/j.eururo.2009.02.021. Epub 2009 Feb 23. Eur Urol. 2009. PMID: 19264390 Review.
-
Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel.Eur Urol. 2018 Jul;74(1):76-83. doi: 10.1016/j.eururo.2018.04.003. Epub 2018 Apr 24. Eur Urol. 2018. PMID: 29703686
Cited by
-
The role of radiotherapy in the management of squamous cell cancer of the penis.World J Urol. 2023 Dec;41(12):3913-3920. doi: 10.1007/s00345-023-04683-7. Epub 2023 Nov 23. World J Urol. 2023. PMID: 37994970 Review.
-
Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study.Transl Androl Urol. 2020 Dec;9(6):2587-2595. doi: 10.21037/tau-20-1044. Transl Androl Urol. 2020. PMID: 33457231 Free PMC article.
-
Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review.Front Oncol. 2022 Mar 23;12:837547. doi: 10.3389/fonc.2022.837547. eCollection 2022. Front Oncol. 2022. PMID: 35402270 Free PMC article.
-
Prognostic Factors of Penile Cancer and the Efficacy of Adjuvant Treatment after Penectomy: Results from a Multi-institution Study.J Korean Med Sci. 2018 Jul 25;33(37):e233. doi: 10.3346/jkms.2018.33.e233. eCollection 2018 Sep 10. J Korean Med Sci. 2018. PMID: 30190657 Free PMC article.
-
Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.Clin Case Rep. 2022 Feb 15;10(2):e05443. doi: 10.1002/ccr3.5443. eCollection 2022 Feb. Clin Case Rep. 2022. PMID: 35223013 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7. - PubMed
-
- Liu JY, Li YH, Zhang ZL, et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol 2013; 31:1519. - PubMed
-
- Graafland NM, van Boven HH, van Werkhoven E, et al. Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol 2010;184:1347. - PubMed
-
- Lughezzani G, Catanzaro M, Torelli T, et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol 2014;191:977. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources